Natco Pharma Reports Mixed Financial Results Amidst Operational Challenges in December 2024

Natco Pharma has recently reported its financial results for the quarter ending December 2024, revealing a complex picture of its performance. The evaluation changes indicate a notable shift in the stock's score, reflecting the challenges faced during this period. On a positive note, Natco Pharma has achieved its highest inventory turnover ratio at 5.89 times over the last five half-yearly periods, showcasing its ability to sell inventory efficiently. Additionally, the company has recorded its highest cash and cash equivalents at Rs 1,562.10 crore, suggesting an improvement in short-term liquidity. Conversely, the financial results also highlight significant challenges. The net sales for the quarter stood at Rs 474.80 crore, marking a substantial decline compared to the average of the previous four quarters. Profit metrics, including profit before tax and profit after tax, have also shown considerable reductions, indicating a negative trend in profitability. Furthermore, the operating profit margin has reached its lowest point in the last five quarters, reflecting a decline in operational efficiency. Overall, Natco Pharma's recent financial results present a mixed landscape, with both strengths and weaknesses evident in its performance metrics. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.